Table 1.
CONSENSUS | INTEROBSERVER | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | MRI |
|
|||||||||||||||||||
Histopathology** | Cytology | IHC | Tissue | Cytology | Diagnosis | ||||||||||||||||
|
|
||||||||||||||||||||
G | SL | SLM | PVL | PVLM | PVLB | LB | NE | V | P1 | P2 | P3 | P1 | P2 | P3 | P1 | P2 | P3 | ||||
1 | Enhancing lesion with a mass effect in the left thalamus | 1 target | 7 targets | 1 target | 1 target | + | Ac | CD20: +++ | B | B | B | Ac | Ac | NDc | D | D | D | ||||
CD3: + | |||||||||||||||||||||
CD3: + | |||||||||||||||||||||
3 | Multiple enhancing lesions in deep gray structures | 2 targets | 4 targets | 2 targets | 1 target | Lc | CD20: +++ | B | B | B | Ac | Ac | NDc | D | D | D | |||||
CD3: + | |||||||||||||||||||||
4 | Enhancing lesion with mass effect in left parietal lobe | 1 target | 2 targets | 3 targets | 3 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | |||||
CD3: + | |||||||||||||||||||||
CD3: + | |||||||||||||||||||||
6 | Multiple enhancing lesions in corpus callosum, right and left parietal lobe | 4 targets | 4 targets | 2 targets | + | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | |||||
CD3: + | |||||||||||||||||||||
7 | Periventricular enhancement | 9 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | ||||||||
CD3: + | |||||||||||||||||||||
8 | Enhancing lesion with mass effect in frontotemporal region | 2 targets | 8 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | |||||||
CD3: + | |||||||||||||||||||||
9 | Enhancing lesion with mass effect in right frontal lobe | 2 targets | 7 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | |||||||
CD3: + | |||||||||||||||||||||
10 | Multiple enhancing lesions in right temporal lobe and thalamus | 1 target | 3 targets | 4 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | ||||||
CD3: + | |||||||||||||||||||||
11 | Enhancing lesion with mass effect in right parietal lobe | 1 target | 5 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | |||||||
CD3: + | |||||||||||||||||||||
12 | Enhancing lesion with mass effect in right parietal lobe | 1 target | 2 targets | 4 targets | Bc | CD20: +++ | B | B | B | Bc | Bc | Bc | D | D | D | ||||||
CD3: + | |||||||||||||||||||||
13 | Periventricular enhancement | 1 target | 1 target | 6 targets | Ac | CD20: +++ | A | A | N | Ac | Ac | NDc | D | D | S | ||||||
CD3:+ | |||||||||||||||||||||
14 | Enhancing lesions in left cerebral hemisphere | 4 targets | 6 targets | Lc | CD20:+++ | N | N | N | NDc | Ac | NDc | ND | ND | ND | |||||||
CD3: + | |||||||||||||||||||||
15 | Enhancing lesion in left thalamus, internal capsule, corpus callosum | 2 targets | 5 targets | 3 targets | Lc | CD20: +++ | B | A | A | Ac | Ac | NDc | D | D | S | ||||||
CD3: + | |||||||||||||||||||||
16 | Left parietal mass with rim enhancement | 5 targets | 2 targets | 1 target | 1 targets | Lc | CD20: ++ | N | N | N | NDc | Ac | NDc | ND | ND | ND | |||||
CD3: ++ | |||||||||||||||||||||
17 | Patchy T2 signal in both hemispheres | 4 targets | 4 targets | 2 targets | Lc | * | A | N | N | NDc | NDc | NDc | S | S | ND | ||||||
CD20: +++ | |||||||||||||||||||||
CD3: + | |||||||||||||||||||||
18 | Enhancing lesion in left-right temporal lobe, corpus callosum | 3 targets | 2 targets | 1 target | 1 target | Lc | CD20: ++ | N | N | N | NDc | NDc | NDc | ND | ND | ND | |||||
CD3: ++ | |||||||||||||||||||||
19 | Multiple enhancing lesions in left thalamus and corpus callosum | 2 targets | 3 targets | 1 target | 1 target | + | Lc | CD20: + | A | N | N | NDc | NDc | NDc | ND | ND | ND | ||||
CD3: +++ | |||||||||||||||||||||
20 | Enhancing lesion in left and right thalamus, internal capsule, corpus cal3losum | 3 targets | 5 targets | 1 target | NLc | CD20: ++ | N | N | N | NDc | NDc | NDc | ND | ND | ND | ||||||
CD3: ++ | |||||||||||||||||||||
21 | Enhancing lesion with mass effect in right frontotemporal region | 5 targets | 5 targets | NLc | CD20: ++ | N | N | N | NDc | NDc | NDc | ND | ND | ND | |||||||
CD3: ++ | |||||||||||||||||||||
22 | Multilocular enhancing lesion with mass effect in right temporal and occipital lobes | 8 targets | NLc | CD20: ++ | N | N | N | NDc | NDc | NDc | ND | ND | ND | ||||||||
CD3: ++ | |||||||||||||||||||||
23 | Enhancing lesion with mass effect in left parietooccipital region | 2 targets | 3 targets | 3 targets | Lc | * | A | A | N | NDc | NDc | NDc | D | S | ND | ||||||
CD20: +++ | |||||||||||||||||||||
CD3: + | |||||||||||||||||||||
24 | Enhancement in left deep structures and contralaterally some small enhancing lesions | 8 targets | NLc | N | N | N | NDc | NDc | NDc | ND | ND | ND | |||||||||
25 | Left deep temporal mass with rim enhancement | 7 targets | NLc | N | N | N | NDc | NDc | NDc | ND | ND | ND |
Co-dominance in SL targets;
Artefacted targets are not included in the table.
G: Non-neoplastic glial tissue. SL:Sparse lymphoid cells. SLM: Sparse macrophages and lymphocytes. PVL: Perivascular normal appearing lymphocytes. PVLM: Perivascular lymphoid cells and macrophages. PVLB: Perivascular lymphocytes intermingled with blasts. LB: Diffuse neoplastic infiltration with blasts. NE: Necrosis V: Infiltration/fragmentation of vessel wall. Ac: Suspicious lymphoid atypia. Lc: Normal lymphocytes with or without macrophages. Bc: Lymphoid cells with blasts. NLc: A few or no lymphoid cells. B: Blasts A: Suspicious atypia. N: Normal appearing lymphocytes. NDc: Non-diagnostic cytology. D: Diagnostic. S: Suspicious. ND: Non-diagnostic. P1: Pathologist 1. P2:Pathologist 2. P3: Pathologist 3.